Susan Bengs1,2, Geoffrey I Warnock1,2, Catherine Gebhard1,2, Ahmed Haider3,4,5, Angela Portmann1,2, Nidaa Mikail1,2, Alexia Rossi1,2, Hazem Ahmed6, Dominik Etter1,2, Valerie Treyer1, Livio Gisler6, Stefanie K Pfister7, Caitlin V M L Jie6, Alexander Meisel1,2, Claudia Keller6, Steven H Liang7, Roger Schibli1,6, Linjing Mu1,6, Ronny R Buechel1, Philipp A Kaufmann1, Simon M Ametamey6. 1. Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. 2. Center for Molecular Cardiology, University of Zurich, 8952, Schlieren, Switzerland. 3. Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. ahmed.haider@usz.ch. 4. Center for Molecular Cardiology, University of Zurich, 8952, Schlieren, Switzerland. ahmed.haider@usz.ch. 5. Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA. ahmed.haider@usz.ch. 6. Institute of Pharmaceutical Sciences, ETH Zurich, 8093, Zurich, Switzerland. 7. Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Abstract
BACKGROUND: Myocardial perfusion imaging by positron emission tomography (PET-MPI) is the current gold standard for quantification of myocardial blood flow. 18F-flurpiridaz was recently introduced as a valid alternative to currently used PET-MPI probes. Nonetheless, optimum scan duration and time interval for image analysis are currently unknown. Further, it is unclear whether rest/stress PET-MPI with 18F-flurpiridaz is feasible in mice. METHODS: Rest/stress PET-MPI was performed with 18F-flurpiridaz (0.6-3.0 MBq) in 27 mice aged 7-8 months. Regadenoson (0.1 µg/g) was used for induction of vasodilator stress. Kinetic modeling was performed using a metabolite-corrected arterial input function. Image-derived myocardial 18F-flurpiridaz uptake was assessed for different time intervals by placing a volume of interest in the left ventricular myocardium. RESULTS: Tracer kinetics were best described by a two-tissue compartment model. K1 ranged from 6.7 to 20.0 mL·cm-3·min-1, while myocardial volumes of distribution (VT) were between 34.6 and 83.6 mL·cm-3. Of note, myocardial 18F-flurpiridaz uptake (%ID/g) was significantly correlated with K1 at rest and following pharmacological vasodilation for all time intervals assessed. However, while Spearman's coefficients (rs) ranged between 0.478 and 0.681, R2 values were generally low. In contrast, an excellent correlation of myocardial 18F-flurpiridaz uptake with VT was obtained, particularly when employing the averaged myocardial uptake from 20 to 40 min post tracer injection (R2 ≥ 0.98). Notably, K1 and VT were similarly sensitive to pharmacological vasodilation induction. Further, mean stress-to-rest ratios of K1, VT, and %ID/g 18F-flurpiridaz were virtually identical, suggesting that %ID/g 18F-flurpiridaz can be used to estimate coronary flow reserve (CFR) in mice. CONCLUSION: Our findings suggest that a simplified assessment of relative myocardial perfusion and CFR, based on image-derived tracer uptake, is feasible with 18F-flurpiridaz in mice, enabling high-throughput mechanistic CFR studies in rodents.
BACKGROUND: Myocardial perfusion imaging by positron emission tomography (PET-MPI) is the current gold standard for quantification of myocardial blood flow. 18F-flurpiridaz was recently introduced as a valid alternative to currently used PET-MPI probes. Nonetheless, optimum scan duration and time interval for image analysis are currently unknown. Further, it is unclear whether rest/stress PET-MPI with 18F-flurpiridaz is feasible in mice. METHODS: Rest/stress PET-MPI was performed with 18F-flurpiridaz (0.6-3.0 MBq) in 27 mice aged 7-8 months. Regadenoson (0.1 µg/g) was used for induction of vasodilator stress. Kinetic modeling was performed using a metabolite-corrected arterial input function. Image-derived myocardial 18F-flurpiridaz uptake was assessed for different time intervals by placing a volume of interest in the left ventricular myocardium. RESULTS: Tracer kinetics were best described by a two-tissue compartment model. K1 ranged from 6.7 to 20.0 mL·cm-3·min-1, while myocardial volumes of distribution (VT) were between 34.6 and 83.6 mL·cm-3. Of note, myocardial 18F-flurpiridaz uptake (%ID/g) was significantly correlated with K1 at rest and following pharmacological vasodilation for all time intervals assessed. However, while Spearman's coefficients (rs) ranged between 0.478 and 0.681, R2 values were generally low. In contrast, an excellent correlation of myocardial 18F-flurpiridaz uptake with VT was obtained, particularly when employing the averaged myocardial uptake from 20 to 40 min post tracer injection (R2 ≥ 0.98). Notably, K1 and VT were similarly sensitive to pharmacological vasodilation induction. Further, mean stress-to-rest ratios of K1, VT, and %ID/g 18F-flurpiridaz were virtually identical, suggesting that %ID/g 18F-flurpiridaz can be used to estimate coronary flow reserve (CFR) in mice. CONCLUSION: Our findings suggest that a simplified assessment of relative myocardial perfusion and CFR, based on image-derived tracer uptake, is feasible with 18F-flurpiridaz in mice, enabling high-throughput mechanistic CFR studies in rodents.
Authors: Padmaja Yalamanchili; Eric Wexler; Megan Hayes; Ming Yu; Jody Bozek; Mikhail Kagan; Heike S Radeke; Michael Azure; Ajay Purohit; David S Casebier; Simon P Robinson Journal: J Nucl Cardiol Date: 2007-10-22 Impact factor: 5.952
Authors: Marc C Huisman; Takahiro Higuchi; Sybille Reder; Stephan G Nekolla; Thorsten Poethko; Hans-Jürgen Wester; Sibylle I Ziegler; David S Casebier; Simon P Robinson; Markus Schwaiger Journal: J Nucl Med Date: 2008-03-14 Impact factor: 10.057
Authors: Ajay Purohit; Heike Radeke; Michael Azure; Kelley Hanson; Richard Benetti; Fran Su; Padmaja Yalamanchili; Ming Yu; Megan Hayes; Mary Guaraldi; Mikhail Kagan; Simon Robinson; David Casebier Journal: J Med Chem Date: 2008-04-19 Impact factor: 7.446
Authors: Ibrahim Danad; Pieter G Raijmakers; Roel S Driessen; Jonathon Leipsic; Rekha Raju; Chris Naoum; Juhani Knuuti; Maija Mäki; Richard S Underwood; James K Min; Kimberly Elmore; Wynand J Stuijfzand; Niels van Royen; Igor I Tulevski; Aernout G Somsen; Marc C Huisman; Arthur A van Lingen; Martijn W Heymans; Peter M van de Ven; Cornelis van Kuijk; Adriaan A Lammertsma; Albert C van Rossum; Paul Knaapen Journal: JAMA Cardiol Date: 2017-10-01 Impact factor: 14.676
Authors: Andrew L Goertzen; Qinan Bao; Mélanie Bergeron; Eric Blankemeyer; Stephan Blinder; Mario Cañadas; Arion F Chatziioannou; Katherine Dinelle; Esmat Elhami; Hans-Sonke Jans; Eduardo Lage; Roger Lecomte; Vesna Sossi; Suleman Surti; Yuan-Chuan Tai; Juan José Vaquero; Esther Vicente; Darin A Williams; Richard Laforest Journal: J Nucl Med Date: 2012-06-14 Impact factor: 10.057
Authors: Ming Yu; Mary T Guaraldi; Mahesh Mistry; Mikhail Kagan; Jennifer L McDonald; Kenneth Drew; Heike Radeke; Michael Azure; Ajay Purohit; David S Casebier; Simon P Robinson Journal: J Nucl Cardiol Date: 2007-10-22 Impact factor: 5.952
Authors: Stefanie D Krämer; Thomas Betzel; Linjing Mu; Ahmed Haider; Adrienne Müller Herde; Anna K Boninsegni; Claudia Keller; Marina Szermerski; Roger Schibli; Bernhard Wünsch; Simon M Ametamey Journal: J Nucl Med Date: 2017-11-30 Impact factor: 10.057
Authors: Simon M Ametamey; Catherine Gebhard; Ahmed Haider; Susan Bengs; Angela Portmann; Alexia Rossi; Hazem Ahmed; Dominik Etter; Geoffrey I Warnock; Nidaa Mikail; Muriel Grämer; Alexander Meisel; Livio Gisler; Caitlin Jie; Claudia Keller; Sebastian Kozerke; Bruno Weber; Roger Schibli; Linjing Mu; Philipp A Kaufmann; Vera Regitz-Zagrosek Journal: Eur J Nucl Med Mol Imaging Date: 2022-01-13 Impact factor: 10.057